These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 21122380)
41. A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib. Xing K; Zhou X; Zhao X; Sun S; Luo Z; Wang H; Yu H; Wang J; Chang J; Wu X; Hu A Med Oncol; 2014 Jul; 31(7):36. PubMed ID: 24908064 [TBL] [Abstract][Full Text] [Related]
42. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735 [TBL] [Abstract][Full Text] [Related]
43. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. Sun L; Zhang Q; Luan H; Zhan Z; Wang C; Sun B J Exp Clin Cancer Res; 2011 Mar; 30(1):30. PubMed ID: 21414214 [TBL] [Abstract][Full Text] [Related]
44. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Kalikaki A; Koutsopoulos A; Trypaki M; Souglakos J; Stathopoulos E; Georgoulias V; Mavroudis D; Voutsina A Br J Cancer; 2008 Sep; 99(6):923-9. PubMed ID: 19238633 [TBL] [Abstract][Full Text] [Related]
45. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Tu HY; Ke EE; Yang JJ; Sun YL; Yan HH; Zheng MY; Bai XY; Wang Z; Su J; Chen ZH; Zhang XC; Dong ZY; Wu SP; Jiang BY; Chen HJ; Wang BC; Xu CR; Zhou Q; Mei P; Luo DL; Zhong WZ; Yang XN; Wu YL Lung Cancer; 2017 Dec; 114():96-102. PubMed ID: 29173773 [TBL] [Abstract][Full Text] [Related]
46. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Zhu CQ; da Cunha Santos G; Ding K; Sakurada A; Cutz JC; Liu N; Zhang T; Marrano P; Whitehead M; Squire JA; Kamel-Reid S; Seymour L; Shepherd FA; Tsao MS; J Clin Oncol; 2008 Sep; 26(26):4268-75. PubMed ID: 18626007 [TBL] [Abstract][Full Text] [Related]
47. The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma. Kim HR; Ahn JR; Lee JG; Bang DH; Ha SJ; Hong YK; Kim SM; Nam KC; Rha SY; Soo RA; Riely GJ; Kim JH; Cho BC Yonsei Med J; 2013 Jul; 54(4):865-74. PubMed ID: 23709419 [TBL] [Abstract][Full Text] [Related]
48. Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups. Zhang Y; Wang Q; Han ZG; Shan L Asian Pac J Cancer Prev; 2013; 14(5):2879-83. PubMed ID: 23803047 [TBL] [Abstract][Full Text] [Related]
49. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients. Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969 [TBL] [Abstract][Full Text] [Related]
50. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785 [TBL] [Abstract][Full Text] [Related]
51. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683 [TBL] [Abstract][Full Text] [Related]
52. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations. Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493 [TBL] [Abstract][Full Text] [Related]
53. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486 [TBL] [Abstract][Full Text] [Related]
54. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Massarelli E; Varella-Garcia M; Tang X; Xavier AC; Ozburn NC; Liu DD; Bekele BN; Herbst RS; Wistuba II Clin Cancer Res; 2007 May; 13(10):2890-6. PubMed ID: 17504988 [TBL] [Abstract][Full Text] [Related]
55. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997 [TBL] [Abstract][Full Text] [Related]
57. EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Yokoyama T; Kondo M; Goto Y; Fukui T; Yoshioka H; Yokoi K; Osada H; Imaizumi K; Hasegawa Y; Shimokata K; Sekido Y Cancer Sci; 2006 Aug; 97(8):753-9. PubMed ID: 16863509 [TBL] [Abstract][Full Text] [Related]
58. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L; Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168 [TBL] [Abstract][Full Text] [Related]
59. EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. Lai Y; Zhang Z; Li J; Sun D; Zhou Y; Jiang T; Han Y; Huang L; Zhu Y; Li X; Yan X Int J Mol Sci; 2013 Dec; 14(12):24549-59. PubMed ID: 24351833 [TBL] [Abstract][Full Text] [Related]